➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Johnson and Johnson
Harvard Business School
AstraZeneca

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BELSOMRA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Belsomra

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02491788 ↗ Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers Recruiting Merck Sharp & Dohme Corp. Phase 4 2016-02-01 The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02491788 ↗ Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers Recruiting Stanford University Phase 4 2016-02-01 The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02491788 ↗ Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers Recruiting VA Palo Alto Health Care System Phase 4 2016-02-01 The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02527564 ↗ Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder Recruiting Merck Sharp & Dohme Corp. Phase 4 2015-09-01 The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.
NCT02527564 ↗ Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder Recruiting Stanford University Phase 4 2015-09-01 The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.
NCT02669030 ↗ A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Not yet recruiting Jefferson Medical College of Thomas Jefferson University Phase 4 2016-02-01 Depression with ongoing insomnia is a common clinical presentation with patients. Clinical data suggests that patients with insomnia that receive concomitant treatment with a sleep aid experience a more robust antidepressant response along with a quicker response. The purpose of this clinical study is to compare the effectiveness of the FDA-approved insomnia medication suvorexant, also known as Belsomra┬«, as add-on treatment to an antidepressant to that of placebo plus antidepressant treatment in patients with depression and residual or ongoing insomnia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Belsomra

Condition Name

Condition Name for Belsomra
Intervention Trials
Insomnia 14
Sleep Disorder 2
Sleep 2
Sleep Initiation and Maintenance Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Belsomra
Intervention Trials
Sleep Initiation and Maintenance Disorders 17
Sleep Wake Disorders 7
Parasomnias 6
Dyssomnias 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Belsomra

Trials by Country

Trials by Country for Belsomra
Location Trials
United States 19
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Belsomra
Location Trials
California 4
Michigan 3
Massachusetts 2
Washington 2
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Belsomra

Clinical Trial Phase

Clinical Trial Phase for Belsomra
Clinical Trial Phase Trials
Phase 4 18
Phase 2/Phase 3 1
Phase 2 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Belsomra
Clinical Trial Phase Trials
Not yet recruiting 16
Recruiting 10
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Belsomra

Sponsor Name

Sponsor Name for Belsomra
Sponsor Trials
Merck Sharp & Dohme Corp. 7
Massachusetts General Hospital 3
Henry Ford Health System 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Belsomra
Sponsor Trials
Other 34
Industry 9
U.S. Fed 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
McKinsey
Baxter
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.